BIOMARKER ANALYSES AND OVERALL SURVIVAL (OS) FROM THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE 3, FASTACT-2 STUDY OF INTERCALATED ERLOTINIB WITH FIRST-LINE CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

Resource

Ann. Oncol., 23, 400-401

Journal

Ann. Oncol.

Journal Issue

23

Pages

400-401

Date Issued

2012

Date

2012

Author(s)

Mok, T. S. K.

Lee, J. S.

Zhang, L.

Yu, C.

Thongprasert, S.

Ladrera, G. E. I.

Srimuninnimit, V.

Truman, M. I.

Klughammer, B.

Wu, Y.

URI

SDGs

[SDGs]SDG3

File(s)

Name

index.html

Size

23.1 KB

Format

HTML

Checksum

(MD5):9578825b65edefbb9fadadb5e2a8ca6b